In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring a number of NNRTI resistance mutations Goals: Doravirine is a just lately licensed HIV-1 NNRTI with improved efficacy, pharmacokinetics and security profile in contrast with efavirenz and restricted cross-resistance with rilpivirine and...